Melanoma and the tumor microenvironment

Current Oncology Reports

Volumn 10, Issue 5, 2008, Pages 439-446

  Villanueva, Jessie ^a   Herlyn, Meenhard ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; BATIMASTAT; BEVACIZUMAB; CEDIRANIB; CHIR 265; CILENGITIDE; CNTO 95; GC 1008; INCYCLINIDE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; ROMIDEPSIN; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UROKINASE; VOLOCIXIMAB; VORINOSTAT; MATRIX METALLOPROTEINASE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER GENETICS; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL INTERACTION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; ENVIRONMENTAL FACTOR; EPIGENETICS; EXTRACELLULAR MATRIX; GENE ACTIVATION; GENE INTERACTION; GENE MUTATION; HUMAN; IMMUNOCOMPETENT CELL; MALIGNANT TRANSFORMATION; MELANOMA; MELANOMA CELL; METASTASIS POTENTIAL; MONOTHERAPY; NONHUMAN; ONCOGENE; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; BIOLOGICAL MODEL; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHENOTYPE; TREATMENT OUTCOME;

CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR MATRIX; HUMANS; MATRIX METALLOPROTEINASES; MELANOMA; MODELS, BIOLOGICAL; MODELS, GENETIC; MUTATION; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PHENOTYPE; TREATMENT OUTCOME;

EID: 55749112156     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0067-y     Document Type: Review

References (50)

1. Tawbi HA, Kirkwood JM: Management of metastatic melanoma. Semin Oncol 2007, 34:532-545.
2. Smalley KS, Lioni M, Noma K, et al.: In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opin Drug Discov 2008, 3:1-10.
3. Haass NK, Smalley KS, Li L, et al.: Adhesion, migration and communication in melanocytes and melanoma. Pigment Cell Res 2005, 18:150-159.
4. Meier F, Schittek B, Busch S, et al.: The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005, 10:2986-3001.
5. Li G, Fukunaga M, Herlyn M: Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling. Exp Cell Res 2004, 297:142-151.
6. Hsu MY, Meier F, Herlyn M: MelanAma development and progression: a conspiracy between tumor and host. Differentiation 2002, 70:522-536.
7. Gottardi CJ, Wong E, Gumbiner BM: E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol 2001, 153:1049-1060.
8. Li G, Satyamoorthy K, Herlyn M: N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001, 61:3819-3825.
9. Larue L, Delmas V: The WNT/beta-catenin pathway in melanoma. Front Biosci 2006, 11:733-742.
10. Widlund HR, Horstmann MA, Price ER, et al.: Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor. J Cell Biol 2002, 158:1079-1087.
11. Delmas V, Beermann F, Martinozzi S, et al.: Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. Genes Dev 2007, 21:2923-2935.
12. Bolos V, Peinado H, Perez-Moreno MA, et al.: The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: A comparison with Snail and E47 repressors. J Cell Sci 2003, 116:499-511.
13. Conacci-Sorrell M, Simcha I, Ben-Yedidia T, et al.: Autoregulation of E-cadherin expression by cadherin-cadherin interactions: The roles of beta-catenin signaling, Slug, and MAPK. J Cell Biol 2003, 163:847-857.
14. Poser I, Dominguez D, de Herreros AG, et al.: Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem 2001, 276:24661-24666.
15. Li G, Schaider H, Satyamoorthy K, et al.: Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. Oncogene 2001, 20:8125-8135.
16. Smit DJ, Gardiner BB, Sturm RA: Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer 2007, 121:2653-2660.
17. Moschos SJ, Drogowski LM, Reppert SL, et al.: Integrins and cancer. Oncology (Williston Park) 2007, 21:13-20.
18. Hess AR, Postovit LM, Margaryan NV, et al.: Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 2005, 65:9851-9860.
19. Villanueva J, Yung Y, Walker JL, et al.: ERK activity and G1 phase progression: Identifying dispensable versus essential activities and primary versus secondary targets. Mol Biol Cell 2007, 18:1457-1463.
20. Stupack DG, Cheresh IA: Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002, 115:3729-3738.
21. Albelda SM, Mette SA, Elder DE, et al.: Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor progression. Cancer Res 1990, 50:6757-6764.
22. Brooks PC, Stromblad S, Sanders LC, et al.: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 1996, 85:683-693.
23. Petitclerc E, Stromblad S, von Schalscha TL, et al.: Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival. Cancer Res 1999, 59:2724-2730.
24. Lawler K, Meade G, O'sullivan G, Kenny D: Shear stress modulates the interaction of platelet-secreted matrix proteins with tumor cells through the integrin alphavbeta3. Am J Physiol Cell Physiol 2004, 287:C1320-C1327.
25. Pilch J, Habermann R, Felding-Habermann B: Unique ability of integrin alpha(v)beta3 to support tumor cell arrest under dynamic flow conditions. J Biol Chem 2002, 277:21930-21938.
26. Conway WC, Van der Voort van Zyp J, Thamilselvan V, et al.: Paxillin modulates squamous cancer cell adhesion and is important in pressure-augmented adhesion. J Cell Biochem 2006, 98:1507-1516.
27. Hart IR, Fidler IJ: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980, 40:2281-2287.
28. Ruiter D, Bogenrieder T, Elder D, et al.: Melanoma-stroma interactions: structural and functional aspects. Lancet Oncol 2002, 3:35-43.
29. Labrousse AL, Ntayi C, Hornebeck W, et al.: Stromal reaction in cutaneous melanoma. Crit Rev Oncol Hematol 2004, 49:269-275.
30. Nesbit M, Nesbit HK, Bennett J, et al.: Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene 1999, 18:6469-6476.
31. Lazar-Molnar E, Hegyesi H, Toth S, et al.: Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000, 12:547-554.
32. Koprowski H, Herlyn M, Balaban G, et al.: Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. Somat Cell Mol Genet 1985, 11:297-302.
33. Bardeesy N, Kim M, Xu J, et al.: Role of epidermal growth factor receptor signaling in RAS-driven melanoma. Mol Cell Biol 2005, 25:4176-4188.
34. Smalley KS, Brafford PA, Herlyn M: Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin Cancer Biol 2005, 15:451-459.
35. Lee JT, Herlyn M: Microenvironmental influences in melanoma progression. J Cell Biochem 2007, 101:862-872.
36. BieTie B, Moses HL: Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006, 6:506-520.
37. Hussein MR: Transforming growth factor-beta and malignant melanoma: molecular mechanisms. J Cutan Pathol 2005, 32:389-395.
38. Berking C, Takemoto R, Schaider H, et al.: Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res 2001, 61:8306-8316.
39. Folkman J: Angiogenesis. Annu Rev Med 2006, 57:1-18.
40. Mahabeleshwar GH, Byzova TV: Angiogenesis in melanoma. Semin Oncol 2007, 34:555-565.
41. Fischer C, Jonckx B, Mazzone M, et al.: Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
42. Ugurel S, Rappl G, Tilgen W, et al.: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001, 19:577-583.
43. Hood JD, Frausto R, Kiosses WB, et al.: Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis. J Cell Biol 2003, 162:933-943.
44. Hofmann UB, Westphal JR, Van Muijen GN, et al.: Matrix metalloproteinases in human melanoma. J Invest Dermatol 2000, 115:337-344.
45. Martin MD, MatrisiPn LM: The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev 2007, 26:717-724.
46. Overall CM, Kleifeld O: TumouV microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 2006, 6:227-239.
47. King J, Zhao J, Clingan P, et al.: Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: Significant survival advantage in patients with musculoskeletal side-effects. Anticancer Res 2003, 23:639-645.
48. Palermo C, Joyce JA: Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci 2008, 29:22-28.
49. Marconi C, Bianchini F, Mannini A, et al.: Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells. Clin Exp Metastasis 2008, 23:225-231.
50. Quintanilla-Dieck MJ, Codriansky K, Keady M, et al.: Cathepsin K in melanoma invasion. J Invest Dermatol 2008, Mar 27 (Epub ahead of print).